Company profile: Mirus Bio
1.1 - Company Overview
Company description
- Provider of nucleic acid-based technologies and gene transfer methods for the pharmaceutical business, including a proprietary RNAi delivery platform and tools for gene expression and biotherapeutic protein. Products include TransIT-VirusGEN for AAV/lentivirus vector production in research and clinical applications, RevIT AAV Enhancer, TransIT-LT1 transfection reagent, and GMP-grade ancillary materials for cell and gene therapy manufacturing.
Products and services
- RevIT AAV Enhancer: Bioreactor-scale additive that boosts AAV titers and percent full capsids, cuts production costs, and doubles doses produced per bioreactor run
- TransIT-VirusGEN Transfection Reagent: Vector-optimized transfection reagent used to produce AAV and lentiviral vectors in research and clinical applications
- GMP Grade Ancillary Materials: GMP-compliant materials ready for use in research and manufacturing processes for cell and gene therapies
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Mirus Bio
DNA Therapeutics
HQ: France
Website
- Description: Provider of clinical-stage biopharmaceutical development as a privately held company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DNA Therapeutics company profile →
Sarepta Therapeutics
HQ: United States
Website
- Description: Provider of precision genetic medicines for rare diseases, including gene therapies for Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and Charcot-Marie-Tooth disease; RNA-targeted exon-skipping therapies for Duchenne muscular dystrophy using PMO and PPMO chemistries; and SareptAssist, a U.S. patient support program for initiating and maintaining therapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sarepta Therapeutics company profile →
4D Molecular Therapeutics
HQ: United States
Website
- Description: Provider of transformative gene therapeutic products enabled by a Therapeutic Vector Evolution Platform using directed evolution to create customized viral vectors for targeted delivery. Offers R100 for retinal diseases, A101 for aerosol lung delivery, and C102 for intravenous heart muscle delivery, plus a product design & development engine and in-house GMP manufacturing and IND-enabling technical operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4D Molecular Therapeutics company profile →
Akouos
HQ: United States
Website
- Description: Provider of AAV vector-based gene therapies to restore and preserve hearing in genetically defined patient populations, addressing causes from single gene mutations to ototoxic drug exposure and aging. Offers AK-OTOF, a gene therapy targeting sensorineural hearing loss due to otoferlin mutations, and the Resonate Program, no-cost genetic testing with optional counseling for auditory neuropathy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akouos company profile →
Neurogene
HQ: United States
Website
- Description: Provider of genetic medicines for neurological disorders, offering EXACT gene therapy technology for controlled and balanced gene expression, a platform that delivers consistent transgene expression (utilized in Rett syndrome) with CNS and ocular delivery, robust CGMP-compliant internal manufacturing for research and clinical material, and clinical trials to evaluate safety and efficacy in genetic diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Neurogene company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Mirus Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Mirus Bio
2.2 - Growth funds investing in similar companies to Mirus Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Mirus Bio
4.2 - Public trading comparable groups for Mirus Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →